Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | USP7 | Q93009 | 2/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | HRH1 | P35367 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17822129 | 0.74 | PIK3CA (0.43) | ALDH1A1 | |
| SCHEMBL17822131 | 0.70 | SLC6A3 (0.34) | KCNH2HRH1CYP2D6CYP3A4 | |
| SCHEMBL2570735 | 0.69 | PIK3CA (0.40) | USP7KCNH2HRH1CYP2D6CYP3A4 | |
| SCHEMBL28030867 | 0.67 | DRD2 (0.45) | ALDH1A1KCNH2HRH1 | |
| SCHEMBL28666083 | 0.62 | DRD2 (0.50) | — | |
| SCHEMBL28835937 | 0.62 | MAPKAPK2 (0.38) | — | |
| SCHEMBL11142301 | 0.61 | — | — | |
| SCHEMBL28072265 | 0.61 | DRD2 (0.42) | — | |
| SCHEMBL28105993 | 0.61 | DRD2 (0.42) | — | |
| SCHEMBL27816652 | 0.61 | DRD2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199637-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | NATCO PHARMA LIMITED (IN) | 2024-06-20 | — | — | US | disclosed |
| EP-4326276-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | Natco Pharma Ltd (IN) | 2024-02-28 | — | — | EP | disclosed |
| EP-3230289-B1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LTD (IN) | 2019-08-14 | — | — | EP | disclosed |
| EP-3230289-B1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LTD (IN) | 2019-08-14 | — | — | EP | disclosed |
| US-10106554-B2 | 7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-C] pyridine derivatives as anticancer drugs | NATCO PHARMA LIMITED (IN) | 2018-10-23 | — | — | US | disclosed |
| US-20170320891-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2017-11-09 | — | — | US | disclosed |
| EP-3230289-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | Natco Pharma Limited (IN) | 2017-10-18 | — | — | EP | disclosed |
| EP-3230289-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | Natco Pharma Limited (IN) | 2017-10-18 | — | — | EP | disclosed |
| EP-3230289-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | Natco Pharma Limited (IN) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016092556-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016092556-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016092556-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106554-B2 | 7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-C] pyridine derivatives as anticancer drugs | PRMT7, CDK7, CASP7 | ALDH1A1 1710/4885USP7 2065/4885KDM5C 266/4885 |
| US-20240199637-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | NR2C2, NRDC, NDC1 | ALDH1A1 3158/4885USP7 3227/4885KDM5C 22/4885 |
| US-20170320891-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | PRMT7, CDK7, CASP7 | ALDH1A1 1710/4885USP7 2065/4885KDM5C 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.